Review paper
CP-189 Infliximab biosimilar: Cost-efficacy analysis
Volume: 23, Issue: Suppl 1, Pages: A83.2 - A84
Published: Feb 14, 2016
Abstract
Background
The biosimilar medicines are identical to authorised biological medicines. The biosimilar infliximab, a TNF-α inhibitor, was approved by the EMA for use in rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis. Studies have shown that the biosimilar of infliximab demonstrates pharmacokinetics and therapeutic equivalence relative to its reference, with lower costs,...Paper Details
Title
CP-189 Infliximab biosimilar: Cost-efficacy analysis
Published Date
Feb 14, 2016
Volume
23
Issue
Suppl 1
Pages
A83.2 - A84
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History